Business Context and Reporting Period
Company: Cardiff Oncology, Inc. (CRDF)
Filing Type: Form 8-K (Current Report)
Date of Report: May 19, 2026
Reporting Period: Event date May 19, 2026
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Events
On May 19, 2026, Cardiff Oncology, Inc. filed a lawsuit against Nerviano Medical Sciences S.r.L (NMS) in the United States District Court for the Southern District of California. The dispute concerns a license agreement for the drug onvansertib.
- NMS Allegation: NMS previously notified Cardiff (February 24, 2026) of a material breach, claiming Cardiff failed to name an NMS employee as a joint inventor on U.S. Patent Nos. 12,144,813 and 12,263,173 and refused to file a joint invention continuation application.
- Cardiff's Position: The Company denies the breach, asserting the agreement does not require naming NMS employees on inventions made exclusively by Cardiff and that doing so would constitute false representations to the U.S. Patent and Trademark Office.
- Relief Sought: Injunctive relief requiring NMS to continue performance under the agreement and a declaratory judgment that Cardiff did not breach the agreement.
Guidance, Outlook, and Risks
Management Commentary: Management states that while discussions with NMS occurred, judicial intervention is now necessary to resolve the dispute.
Risks and Contingencies: The outcome of the litigation could impact the Company's rights to the onvansertib license and related patents. The filing does not provide specific financial guidance or outlook beyond the immediate legal event.
Investor Verification Checklist
- Verify the status of the license agreement for onvansertib and potential impacts on commercialization rights.
- Review the specific terms of the agreement regarding inventorship and joint patent applications.
- Monitor future court filings for updates on the declaratory judgment and injunctive relief requests.
- Assess the potential financial impact of litigation costs and any disruption to the onvansertib program.